Michael Kershaw
Associate Professor
Medicine
Peter MacCallum Cancer Centre
Australia
Biography
Associate Professor Michael Kershaw is a Group Leader and Head of the Immune Innovation Laboratory at the Peter MacCallum Cancer Centre. Michael received a PhD from the University of Melbourne in 1997 for his studies into the genetic redirection of immunity against cancer. He performed Postdoctoral studies in cancer immunotherapy in the laboratories of Dr Steven Rosenberg at the National Cancer Institute in Bethesda, Maryland from 1998 to 2001. He returned to Australia in 2002 and took up a position in the Cancer Immunology Program at Peter Mac. Michael’s laboratory is involved in the development of effective immunotherapies for cancer. The approaches involve novel in-house derived strategies and new ways of using existing immunomodulatory reagents. Using these approaches in mouse tumour models, he seeks to determine the cellular and molecular mechanisms of immune-mediated anti-tumour effects. The principal research interests of the lab lie in understanding the tumour microenvironment and in the use of adoptive immunotherapy and vaccines for cancer treatment.
Research Interest
Cancer Immunology
Publications
-
CAR T-cell therapy of solid tumors. Yong CSM, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH. Immunol Cell Biol. 2017 Apr;95(4):356-363.
-
A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. Mardiana S, John LB, Henderson MA, Slaney CY, von Scheidt B, Giuffrida L, Davenport AJ, Trapani JA, Neeson PJ, Loi S, Haynes NM, Kershaw MH, Beavis PA, Darcy PK. Cancer Res. 2017 Mar 15;77(6):1296-1309.
-
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, Johnstone RW, Trapani JA, Stagg J, Loi S, Kats L, Gyorki D, Kershaw MH, Darcy PK. J Clin Invest. 2017 Mar 1;127(3):929-941.
